[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597653":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":25,"locations":33,"responsibleParty":148,"collaborators":11,"id":150,"slug":151,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":11,"eligibilityCriteria":156,"healthyVolunteers":152,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":11,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of KarXT","EXPERIMENTAL",null,[13],"Drug: KarXT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","KarXT","Specified dose on specified days",[9],[21],"BMS-986510",[23],{"name":5,"affiliation":5,"role":24},"STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":32,"role":28,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[34,52,66,79,93,106,120,134],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Collaborative Neuroscience Research, LLC","RECRUITING","Los Alamitos","California","90720-3118","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.07256,33.80307,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":51,"phoneExt":11,"email":11},"David Walling, Site 0001","714-799-7799",{"facility":53,"status":36,"city":54,"state":55,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Research Centers of America ( Hollywood )","Hollywood","Florida","33024",{"type":43,"coordinates":58},[59,60],-80.14949,26.0112,{"lat":60,"lon":59},[63],{"name":64,"role":28,"phone":65,"phoneExt":11,"email":11},"Edwin Gomez, Site 0005","954-990-7649",{"facility":67,"status":36,"city":68,"state":55,"zip":69,"country":40,"countryCode":41,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Innovative Clinical Research, Inc.","Miami Lakes","33016",{"type":43,"coordinates":71},[72,73],-80.30866,25.90871,{"lat":73,"lon":72},[76],{"name":77,"role":28,"phone":78,"phoneExt":11,"email":11},"Rishi Kakar, Site 0004","786-512-4106",{"facility":80,"status":36,"city":81,"state":82,"zip":83,"country":40,"countryCode":41,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Atlanta Center for Medical Research","Atlanta","Georgia","30331",{"type":43,"coordinates":85},[86,87],-84.38798,33.749,{"lat":87,"lon":86},[90],{"name":91,"role":28,"phone":92,"phoneExt":11,"email":11},"Elyssa Barron, Site 0008","404-881-5800",{"facility":94,"status":36,"city":95,"state":82,"zip":96,"country":40,"countryCode":41,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"CenExel iResearch, LLC","Decatur","30030",{"type":43,"coordinates":98},[99,100],-84.29631,33.77483,{"lat":100,"lon":99},[103],{"name":104,"role":28,"phone":105,"phoneExt":11,"email":11},"Kimball Johnson, Site 0003","312-942-5592",{"facility":107,"status":36,"city":108,"state":109,"zip":110,"country":40,"countryCode":41,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Uptown Research Institute","Chicago","Illinois","60640",{"type":43,"coordinates":112},[113,114],-87.65005,41.85003,{"lat":114,"lon":113},[117],{"name":118,"role":28,"phone":119,"phoneExt":11,"email":11},"John Sonnenberg, Site 0002","773-968-9868",{"facility":121,"status":36,"city":122,"state":123,"zip":124,"country":40,"countryCode":41,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Hassman Research Institute Marlton Site","Marlton","New Jersey","08053",{"type":43,"coordinates":126},[127,128],-74.92183,39.89122,{"lat":128,"lon":127},[131],{"name":132,"role":28,"phone":133,"phoneExt":11,"email":11},"Elan Cohen, Site 0007","856-452-9901",{"facility":135,"status":36,"city":136,"state":137,"zip":138,"country":40,"countryCode":41,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Community Clinical Research","Austin","Texas","78754",{"type":43,"coordinates":140},[141,142],-97.74306,30.26715,{"lat":142,"lon":141},[145],{"name":146,"role":28,"phone":147,"phoneExt":11,"email":11},"David Brown, Site 0006","512-323-2622",{"type":149,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100597653","phase-1-a-study-to-evaluate-the-safety-tolerability-and-pk-of-an-injectable-form-of-karxt-100597653",false,"NCT07061288","A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT","An Open-label, Phase 1, Dose-Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of a Long-Acting Injectable KarXT Formulation in Participants With Schizophrenia","Inclusion Criteria\n\n* Participants must have a primary diagnosis of schizophrenia, as confirmed by psychiatric evaluation based on Diagnostic and Statistical Manual of Mental Disorders (5th Edition, Text Revision) (DSM-5-TR) criteria and Mini International Neuropsychiatric Interview (MINI) (version 7.0.2).\n* Participants must have a Positive and Negative Syndrome Scale (PANSS) total score ≤ 80 and a Clinical Global Impression - Severity (CGI-S) score ≤ 4 at both screening and baseline.\n* Participants must have a body mass index (BMI) between 18 and 40 kg\u002Fm².\n* Participants should be willing and able, as determined by the investigator, to discontinue all antipsychotic medications prior to the baseline visit and must be able to comply with all protocol requirements.\n\nExclusion Criteria\n\n* Participants must not have newly diagnosed schizophrenia or a first treated episode of schizophrenia.\n* Participants must not have any other DSM-5-TR disorder diagnosed within the past 12 months, such as major depressive disorder or bipolar disorder.\n* Participants must not have a history of alcohol or drug use disorder within the past 12 months or those with clinically significant disease or disorder that would jeopardize their safety or affect the validity of study results.\n* Participants must not be at risk for suicidal behavior.\n* Female participants must not be pregnant or breastfeeding.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years","55 Years",{"count":161,"type":162},116,"ESTIMATED","INTERVENTIONAL",[165],"PHASE1","A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia",[168],"Schizophrenia",[17,170,171],"Long-acting injectable (LAI)","Cobenfy","2026-06-11",{"date":174,"type":175},"2026-06-12","ACTUAL",{"date":177,"type":175},"2025-09-03",{"date":179,"type":162},"2027-10-15",{"name":5,"class":6},8]